Non-small-cellLungCancer.PDFVIP

Original Article 559 A Randomized Study of Gemcitabine plus Cisplatin and Vinorelbine plus Cisplatin in Patients with Advanced Non-small-cell Lung Cancer John Wen-Cheng Chang, MD; Thomas Chang-Yao Tsao1, MD, PhD; Cheng-Ta Yang2, MD; Meng-Chih Lin3, MD; Yun-Chung Cheung4, MD; Chung-Chi Liaw, MD; Chih-Hung Chen5, MD Background: Gemcitabine plus cisplatin (GC) and vinorelbine plus cisplatin (VC) are active and well-tolerated regimens for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). We conducted this study to compare the safety and efficacy of these regimens as front-line chemothera- py for patients with NSCLC. Methods: Eligible patients were randomized to receive either gemcitabine (1000 mg/m2) on days 1, 8, and 15 plus cisplatin (80 mg/m2) on day 15 (arm GC), or vinorelbine (20 mg/m2) on days 1, 8, and 15 plus cisplatin (80 mg/m2) on day 15 (arm VC). Treatments were repeated every 28 days. The costs of treatment were retrieved from the Health Care Reporting System of Chang Gung Memorial Hospital at the time of final data analysis. Results: Eighty-three patients (GC, n = 39; VC, n = 44) were enrolled in the study. Seventy-three patients were analyzed. Response rates were 38% and 31% and median survivals were 12.9 and 9.0 months for the 34 patients in the GC arm and 39 patients in the VC arm, respectively. One-year survival was 55.9% in the GC arm and 33.3% in the VC arm. There was no difference in the response rate (p = 0.622), progression free survival (p = 0.443) and medi- a